How This GLP-1 Weight Loss Calculator Works — and What the Data Actually Shows

GLP-1 receptor agonists are a class of injectable and oral medications that mimic the glucagon-like peptide-1 hormone your gut produces naturally after eating. This hormone signals your brain to reduce appetite, slows gastric emptying (meaning food stays in your stomach longer, keeping you fuller), and triggers insulin release in response to elevated blood sugar. Drugs in this class — including semaglutide (sold as Ozempic for diabetes and Wegovy for obesity) and tirzepatide (Mounjaro for diabetes and Zepbound for obesity) — were originally developed for Type 2 diabetes management. When researchers analyzed body weight data in those early trials, the results were striking enough to launch a new chapter in obesity medicine.

This calculator uses published phase 3 clinical trial efficacy curves as its foundation, then applies personalized adjustment factors based on your biological sex, age, diabetes status, and self-reported lifestyle adherence to generate a week-by-week weight projection specific to your starting weight and height.

The Four Phases of GLP-1 Weight Loss — What to Expect Each Month

Weight loss on GLP-1 medications follows a predictable biological pattern that is fundamentally different from traditional calorie restriction. Understanding this trajectory helps set realistic expectations and prevents early discontinuation — the single biggest reason people fail to see full clinical benefit.

• Weeks 1–4 (Low-dose titration): All GLP-1 medications begin at sub-therapeutic starter doses to reduce nausea and GI distress. Appetite suppression at this stage is mild. Most people lose 1–4 lbs, primarily from reduced fluid retention and early caloric restriction. If you feel the drug "isn't working" at week 2, this is entirely normal.
• Weeks 5–20 (Dose escalation): Doses increase every 4 weeks on a fixed titration schedule. As you approach the full therapeutic dose, hunger suppression intensifies significantly. This is when most people experience their most rapid weekly weight loss — typically 1–2 lbs per week. Energy intake drops substantially, and many patients report food "noise" (constant food thoughts) diminishing dramatically.
• Weeks 20–52 (Full therapeutic dose): You are now at the target dose. Weight loss continues but decelerates as your body adapts to the new equilibrium. The rate typically drops to 0.3–0.7 lbs per week. The STEP 1 trial showed peak cumulative weight loss occurring between weeks 48 and 68, with a slight plateau afterward.
• After week 52+ (Maintenance or late-phase): Most people stabilize or continue losing at a very slow rate. Clinical trials at 72 weeks (SURMOUNT-1) show continued modest loss, but the majority of total weight lost occurs in the first 52 weeks. Discontinuation at this stage results in rapid weight regain — typically recovering 65–70% of lost weight within 12 months, per the STEP 4 extension trial.

How Biological Sex Affects GLP-1 Weight Loss Results

Clinical subgroup analyses from the STEP 1 trial reveal a meaningful sex-based difference in semaglutide outcomes: female participants lost an average of 16.0% of body weight at 68 weeks, compared to 13.4% for male participants — a 2.6 percentage point gap. This difference persists even after controlling for baseline BMI, age, and adherence. Researchers believe it reflects differences in body fat distribution (women tend to carry more subcutaneous fat, which is more metabolically responsive to GLP-1 therapy), baseline hormonal environment, and possibly sex-differentiated gut hormone responses. This calculator applies a sex-specific adjustment factor derived from published STEP 1 and SURMOUNT-1 subgroup data.

Why Type 2 Diabetes Reduces GLP-1 Weight Loss Potential

People with Type 2 diabetes consistently lose less weight on GLP-1 medications than people without diabetes at equivalent doses. The gap is approximately 2–4 percentage points of total body weight. In the SUSTAIN trials of semaglutide 1mg for T2D management, average weight loss was 4.5–6.5 kg — substantially less than the 15.3 kg average in STEP 1, even acknowledging the dose difference. The mechanism is multifactorial: insulin resistance blunts the metabolic response to caloric restriction, baseline hyperglycemia causes water retention that obscures early fat loss on the scale, and competing glucose-management effects of GLP-1 drugs (reduced hepatic glucose output, improved insulin secretion) may partially attenuate the pure weight-loss signal.

Semaglutide vs. Tirzepatide: A Detailed Comparison of Weight Loss Outcomes

The most consequential question in GLP-1 prescribing in 2024–2025 is whether tirzepatide outperforms semaglutide for weight loss. The short answer: yes, meaningfully so. But the clinical picture is more nuanced than headline percentages suggest.

Tirzepatide differs from semaglutide in a critical way: it is a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GIP was long considered a relatively minor metabolic hormone, but the SURMOUNT trials revealed that dual GLP-1/GIP activation produces synergistic weight loss effects that exceed either pathway alone. The mechanism appears to involve enhanced fatty acid oxidation in adipose tissue and additive reductions in energy intake beyond what GLP-1 agonism alone achieves.

When Semaglutide May Be the Better Choice

Despite tirzepatide's superior weight loss numbers, semaglutide remains the appropriate choice for many patients. Key reasons include: established cardiovascular outcome data (semaglutide's SELECT trial showed statistically significant reduction in MACE — major adverse cardiovascular events — in non-diabetic patients with established CVD, while tirzepatide's equivalent trial is ongoing); broader insurance prior authorization coverage in many US states and employer health plans; longer post-market safety experience; and potentially better individual GI tolerability for some patients. The SELECT trial cardiovascular finding represents a meaningful clinical differentiator that goes beyond weight loss numbers alone.

Liraglutide (Saxenda): The Established First Option, Now Largely Superseded

Liraglutide 3mg (Saxenda) received FDA approval for chronic weight management in December 2014, making it the first GLP-1 drug specifically indicated for obesity. The SCALE trial demonstrated an average 8.4% total body weight loss over 56 weeks in non-diabetic patients — a result that was groundbreaking at the time. Today, in the context of 15–21% results with newer agents, Saxenda is used primarily when semaglutide and tirzepatide are not accessible due to cost or insurance restrictions, or when patients cannot tolerate once-weekly injections and prefer a daily lower-dose regimen during a transition period. Its daily injection requirement and comparatively modest efficacy have made it a secondary option in most clinical settings.

Understanding BMI and Health Milestones on GLP-1 Therapy

Why the 5%, 10%, and 15% Weight Loss Thresholds Actually Matter

Obesity medicine researchers have identified specific percentage weight loss thresholds at which distinct health improvements emerge. These are not arbitrary round numbers — they reflect real phase transitions in metabolic and cardiovascular risk reduction that have been consistently observed across multiple clinical populations.

Losing 5% of body weight is the threshold at which most obesity-related comorbidities begin to measurably improve. A 2016 analysis published in Cell Metabolism demonstrated that 5% weight loss reliably reduces fasting insulin and blood glucose, lowers systolic blood pressure by an average of 3–5 mmHg, reduces hepatic fat accumulation, and improves fasting LDL cholesterol. Nearly all GLP-1 trial participants on therapeutic doses reach this milestone.

At 10% body weight loss, sleep apnea severity typically improves enough to reduce CPAP pressure requirements, joint pain — particularly in the knees and hips — begins to decrease meaningfully (each pound of body weight exerts approximately 4 pounds of compressive force on the knee joint during walking), and mobility and functional capacity improve. Many patients report their first significant quality-of-life improvements at this threshold.

At 15%+ body weight loss, cardiovascular risk reduction becomes substantial. The SELECT trial demonstrated that even the population-average 9.4% weight loss achieved with semaglutide in that study was associated with a 20% relative risk reduction in MACE. Extrapolating from that data, 15%+ loss is associated with risk reduction previously achievable only through major lifestyle interventions or surgical procedures.

At 20%+ body weight loss — now achievable for many patients on tirzepatide 15mg — outcomes approach those historically associated with metabolic bariatric surgery. The SURMOUNT-1 trial showed 56.8% of participants achieving at least 20% weight loss, and 36.2% achieving at least 25%. This scale of weight loss can result in remission of Type 2 diabetes, resolution of sleep apnea, normalization of blood pressure, and dramatic improvements in mobility and quality of life.

Reading Your BMI Results in Context

This calculator tracks your BMI trajectory across the standard US classification system: Underweight (below 18.5), Normal weight (18.5–24.9), Overweight (25.0–29.9), Obese Class I (30.0–34.9), Obese Class II (35.0–39.9), and Obese Class III (40.0 and above). Moving from one BMI category to a lower one during GLP-1 therapy is clinically meaningful and often corresponds to visible health improvements, but BMI has important limitations as an individual health metric. It does not account for muscle mass, bone density, body fat distribution, or ethnicity-specific health risk thresholds. A person moving from BMI 32 to BMI 28 has made meaningful health progress even though both values are technically in the "obese" or "overweight" range by US standards.

Managing Side Effects and Getting the Most Out of GLP-1 Therapy

Complete Side Effect Profile With Frequencies

GLP-1 medications share a common side effect profile driven primarily by slowed gastric emptying and direct effects on the brain's nausea centers. The following frequency data is from the STEP 1 semaglutide 2.4mg trial; tirzepatide shows a qualitatively similar profile with slightly higher rates of nausea at equivalent weight-loss doses.

Source: Wilding et al. (2021), STEP 1 trial, NEJM. Side effects classified as mild-to-moderate in >80% of cases. Serious adverse events were rare and not significantly different from placebo in the STEP 1 trial.

Evidence-Based Strategies to Minimize GI Side Effects

• Eat smaller, more frequent meals — GLP-1 medications dramatically slow gastric emptying, so a meal that would have been comfortable at your previous eating speed may cause nausea once you have eaten past your new satiety signals
• Avoid fried foods, high-fat meals, and heavily spiced foods particularly during the first 12 weeks — these categories are most strongly associated with GLP-1-related GI distress
• Eat slowly and stop at the first sign of fullness — many nausea episodes are caused by overeating relative to the slower gastric emptying rate, not by the medication itself
• Stay consistently hydrated throughout the day — dehydration worsens nausea and contributes significantly to constipation on GLP-1 therapy
• Inject on a consistent day each week — stable drug levels reduce peak-concentration nausea that can accompany erratic dosing
• If nausea is severe enough to miss doses, speak with your prescriber — temporary dose reduction or anti-nausea medication (ondansetron is commonly used) can bridge patients through the escalation phase without losing therapeutic momentum
• Never skip injections as a side effect management strategy — irregular dosing maintains side effects without delivering consistent therapeutic benefit

Muscle Loss on GLP-1 Therapy — and How to Prevent It

One underappreciated aspect of GLP-1 weight loss is that rapid weight reduction — like any form of aggressive caloric restriction — causes some degree of lean muscle mass loss alongside fat loss. In the STEP 1 trial, approximately 40% of total weight lost was lean body mass, compared to 20–25% with slower diet-and-exercise interventions. This is clinically significant because muscle mass drives metabolic rate, functional strength, and long-term weight maintenance.

The most effective countermeasure is progressive resistance training (weight lifting or body weight strength training) performed at least 2–3 times per week throughout your GLP-1 therapy. Evidence from multiple studies shows that combining resistance training with GLP-1 treatment significantly reduces the proportion of lean mass lost during weight reduction, preserves functional strength, and improves body composition beyond what the scale alone captures. Adequate protein intake — most experts recommend 1.2–1.6 grams of protein per kilogram of goal body weight per day — is equally critical. GLP-1 medications can suppress appetite enough that many patients are not eating sufficient protein, which accelerates muscle loss even with training.

Frequently Asked Questions About GLP-1 Weight Loss